ANBL1531: The Children’s Oncology Group (COG) Experience Using a Bayesian Approach

Arlene Naranjo; Rochelle Bagatell; Emily G. Greengard; Steven G. DuBois

doi:10.1201/9781003288640-2

ANBL1531: The Children’s Oncology Group (COG) Experience Using a Bayesian Approach

Arlene Naranjo, Rochelle Bagatell, Emily G. Greengard, Steven G. DuBois

Pediatrics - Hematology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

ANBL1531 is a COG multiarm umbrella-type phase III clinical trial in children with newly diagnosed high-risk neuroblastoma. ANBL1531 is designed to simultaneously address multiple scientific questions about the benefits of adding ¹³¹I-metaiodobenzylguanidine (MIBG) or a targeted inhibitor of signaling via the anaplastic lymphoma kinase (ALK) pathway to improve outcomes. ANBL1531 has five treatment arms. Two arms are nonrandom treatment assignments for patients who either have ALK-aberrant or MIBG non-avid disease. This chapter focuses on the remaining three arms, which are randomized treatment assignments for patients with MIBG-avid and ALK wild-type disease.

Original language	English (US)
Title of host publication	Case Studies in Innovative Clinical Trials
Publisher	CRC Press
Pages	19-27
Number of pages	9
ISBN (Electronic)	9781000987218
ISBN (Print)	9781032262659
DOIs	https://doi.org/10.1201/9781003288640-2
State	Published - Jan 1 2023

Bibliographical note

Publisher Copyright:
© 2024 selection and editorial matter, Kristine Broglio and Binbing Yu.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1201/9781003288640-2

OpenUrl availability

Full text

Cite this

@inbook{8cf2c33880064566a8438ca276b3b4a7,

title = "ANBL1531: The Children{\textquoteright}s Oncology Group (COG) Experience Using a Bayesian Approach",

abstract = "ANBL1531 is a COG multiarm umbrella-type phase III clinical trial in children with newly diagnosed high-risk neuroblastoma. ANBL1531 is designed to simultaneously address multiple scientific questions about the benefits of adding 131I-metaiodobenzylguanidine (MIBG) or a targeted inhibitor of signaling via the anaplastic lymphoma kinase (ALK) pathway to improve outcomes. ANBL1531 has five treatment arms. Two arms are nonrandom treatment assignments for patients who either have ALK-aberrant or MIBG non-avid disease. This chapter focuses on the remaining three arms, which are randomized treatment assignments for patients with MIBG-avid and ALK wild-type disease.",

author = "Arlene Naranjo and Rochelle Bagatell and Greengard, {Emily G.} and DuBois, {Steven G.}",

note = "Publisher Copyright: {\textcopyright} 2024 selection and editorial matter, Kristine Broglio and Binbing Yu.",

year = "2023",

month = jan,

day = "1",

doi = "10.1201/9781003288640-2",

language = "English (US)",

isbn = "9781032262659",

pages = "19--27",

booktitle = "Case Studies in Innovative Clinical Trials",

publisher = "CRC Press",

}

TY - CHAP

T1 - ANBL1531

T2 - The Children’s Oncology Group (COG) Experience Using a Bayesian Approach

AU - Naranjo, Arlene

AU - Bagatell, Rochelle

AU - Greengard, Emily G.

AU - DuBois, Steven G.

PY - 2023/1/1

Y1 - 2023/1/1

N2 - ANBL1531 is a COG multiarm umbrella-type phase III clinical trial in children with newly diagnosed high-risk neuroblastoma. ANBL1531 is designed to simultaneously address multiple scientific questions about the benefits of adding 131I-metaiodobenzylguanidine (MIBG) or a targeted inhibitor of signaling via the anaplastic lymphoma kinase (ALK) pathway to improve outcomes. ANBL1531 has five treatment arms. Two arms are nonrandom treatment assignments for patients who either have ALK-aberrant or MIBG non-avid disease. This chapter focuses on the remaining three arms, which are randomized treatment assignments for patients with MIBG-avid and ALK wild-type disease.

AB - ANBL1531 is a COG multiarm umbrella-type phase III clinical trial in children with newly diagnosed high-risk neuroblastoma. ANBL1531 is designed to simultaneously address multiple scientific questions about the benefits of adding 131I-metaiodobenzylguanidine (MIBG) or a targeted inhibitor of signaling via the anaplastic lymphoma kinase (ALK) pathway to improve outcomes. ANBL1531 has five treatment arms. Two arms are nonrandom treatment assignments for patients who either have ALK-aberrant or MIBG non-avid disease. This chapter focuses on the remaining three arms, which are randomized treatment assignments for patients with MIBG-avid and ALK wild-type disease.

UR - http://www.scopus.com/inward/record.url?scp=85177513800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85177513800&partnerID=8YFLogxK

U2 - 10.1201/9781003288640-2

DO - 10.1201/9781003288640-2

M3 - Chapter

AN - SCOPUS:85177513800

SN - 9781032262659

SP - 19

EP - 27

BT - Case Studies in Innovative Clinical Trials

PB - CRC Press

ER -

ANBL1531: The Children’s Oncology Group (COG) Experience Using a Bayesian Approach

Abstract

Bibliographical note

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this